{"id":"technetium-tc-99m-tilmanocept","rwe":[{"pmid":"29999773","year":"2006","title":"Technetium Tc 99m Tilmanocept.","finding":"","journal":"","studyType":"Clinical Study"},{"pmid":"35958955","year":"2022","title":"Technetium Tc 99m tilmanocept fails to detect sentinel lymph nodes in endometrial cancer.","finding":"","journal":"Gynecologic oncology reports","studyType":"Clinical Study"},{"pmid":"28204544","year":"2017","title":"Application of a Novel CD206+ Macrophage-Specific Arterial Imaging Strategy in HIV-Infected Individuals.","finding":"","journal":"The Journal of infectious diseases","studyType":"Clinical Study"}],"tags":[{"label":"Radioactive Diagnostic Agent","category":"class"},{"label":"Biologic","category":"modality"},{"label":"V09IA09","category":"atc"},{"label":"Active","category":"status"},{"label":"Diagnostic aid","category":"indication"},{"label":"Navidea Biopharms","category":"company"},{"label":"Approved 2010s","category":"decade"}],"phase":"marketed","safety":{"safetySignals":[{"llr":336.182,"date":"","count":111,"signal":"Drug ineffective","source":"DrugCentral FAERS","actionTaken":"Reported 111 times (LLR=336)"}],"commonSideEffects":[{"effect":"Injection site irritation","drugRate":"0.7%","severity":"common","organSystem":""},{"effect":"Injection site pain","drugRate":"0.2%","severity":"common","organSystem":""}],"seriousAdverseEvents":[]},"trials":[],"aliases":[],"company":"Navidea Biopharms","patents":[{"source":"FDA Orange Book via DrugCentral","expires":"2029-01-30","territory":"US","patentNumber":"9439985"},{"source":"FDA Orange Book via DrugCentral","expires":"2025-05-12","territory":"US","patentNumber":"6409990"}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=TECHNETIUM TC 99M TILMANOCEPT","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:33:26.969919+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:33:26.969759+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:33:33.356893+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TECHNETIUM TC 99M TILMANOCEPT","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:33:34.012799+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108726/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:33:34.638382+00:00"}},"allNames":"lymphoseek kit","offLabel":[],"synonyms":["technetium TC-99m tilmanocept","technetium Tc 99m tilmanocept","lymphoseek","technetium (99mTc) tilmanocept"],"timeline":[{"date":"2013-03-13","type":"positive","source":"DrugCentral","milestone":"FDA approval (Navidea Biopharms)"}],"aiSummary":"Lymphoseek Kit (Technetium TC 99M Tilmanocept) is a radioactive diagnostic agent developed by Navidea Biopharmaceuticals. It is a small molecule that works by binding to specific targets in the body, allowing for imaging of lymph nodes. Lymphoseek Kit is FDA-approved for use as a diagnostic aid, and its commercial status is patented. Key safety considerations include radiation exposure and potential allergic reactions. It is used to help identify cancerous lymph nodes.","approvals":[{"date":"2013-03-13","orphan":false,"company":"NAVIDEA BIOPHARMS","regulator":"FDA"}],"brandName":"Lymphoseek Kit","ecosystem":[{"indication":"Diagnostic aid","otherDrugs":[{"name":"ceruletide","slug":"ceruletide","company":"Pharmacia And Upjohn"},{"name":"iopanoic acid","slug":"iopanoic-acid","company":""},{"name":"iopodic acid","slug":"iopodic-acid","company":"Bracco"},{"name":"sincalide","slug":"sincalide","company":"Bracco"}],"globalPrevalence":null}],"mechanism":{"novelty":"Follow-on","moaClass":"Radiopharmaceutical Activity","modality":"Biologic","drugClass":"Radioactive Diagnostic Agent","explanation":"","oneSentence":"","technicalDetail":"Lymphoseek Kit is a small molecule that binds to CD206, a receptor found on the surface of certain immune cells in the lymph nodes, allowing for targeted imaging of these cells."},"commercial":{"launchDate":"2013","_launchSource":"DrugCentral (FDA 2013-03-13, NAVIDEA BIOPHARMS)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4755","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=TECHNETIUM%20TC%2099M%20TILMANOCEPT","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TECHNETIUM TC 99M TILMANOCEPT","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:48:40.414788","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:33:36.556766+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"arcitumomab","drugSlug":"arcitumomab","fdaApproval":"1996-06-28","relationship":"same-class"}],"genericName":"technetium tc 99m tilmanocept","indications":{"approved":[{"name":"Diagnostic aid","source":"DrugCentral","snomedId":2949005,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"arcitumomab","brandName":"arcitumomab","genericName":"arcitumomab","approvalYear":"1996","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07159074","phase":"PHASE2","title":"Repurposing Tilmanocept for Cardiac Sarcoidosis","status":"RECRUITING","sponsor":"Duke University","startDate":"2025-09-17","conditions":["Cardiac Sarcoidosis"],"enrollment":15,"completionDate":"2026-12-31"},{"nctId":"NCT07121595","phase":"PHASE2","title":"Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial","status":"RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2025-07-17","conditions":["Oral Cavity Squamous Cell Carcinoma","Stage I Lip and Oral Cavity Cancer AJCC v8","Stage II Lip and Oral Cavity Cancer AJCC v8","Stage III Lip and Oral Cavity Cancer AJCC v8","Stage IVA Lip and Oral Cavity Cancer AJCC v8"],"enrollment":50,"completionDate":"2030-07-01"},{"nctId":"NCT03157167","phase":"PHASE1","title":"An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)","status":"COMPLETED","sponsor":"Navidea Biopharmaceuticals","startDate":"2017-12-01","conditions":["Kaposi Sarcoma","HIV Infections"],"enrollment":15,"completionDate":"2020-03-30"},{"nctId":"NCT05246280","phase":"PHASE3","title":"Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA","status":"TERMINATED","sponsor":"Navidea Biopharmaceuticals","startDate":"2022-03-02","conditions":["Rheumatoid Arthritis"],"enrollment":169,"completionDate":"2024-07-09"},{"nctId":"NCT04947137","phase":"PHASE2","title":"Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m Tilmanocept","status":"COMPLETED","sponsor":"Navidea Biopharmaceuticals","startDate":"2021-05-27","conditions":["Rheumatoid Arthritis"],"enrollment":134,"completionDate":"2022-01-21"},{"nctId":"NCT04078191","phase":"PHASE2","title":"Comparison of Tc 99m Tilmanocept Imaging With IHC Analysis of CD206 Expression in Synovial Tissue of Subjects With RA","status":"TERMINATED","sponsor":"Navidea Biopharmaceuticals","startDate":"2021-09-14","conditions":["Rheumatoid Arthritis"],"enrollment":20,"completionDate":"2024-07-09"},{"nctId":"NCT03332940","phase":"PHASE1","title":"Safety Evaluation of IV Tc 99m Tilmanocept and Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH","status":"TERMINATED","sponsor":"Navidea Biopharmaceuticals","startDate":"2017-12-06","conditions":["Nonalcoholic Steatohepatitis","NASH - Nonalcoholic Steatohepatitis"],"enrollment":6,"completionDate":"2019-03-10"},{"nctId":"NCT02509598","phase":"PHASE2","title":"A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping","status":"COMPLETED","sponsor":"Cardinal Health 414, LLC","startDate":"2015-08","conditions":["Rhabdomyosarcoma","Melanoma"],"enrollment":24,"completionDate":"2019-03-06"},{"nctId":"NCT05241522","phase":"PHASE1","title":"Dosimetry of Tc-99m-Tilmanocept","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2021-08-06","conditions":["Diabetic Kidney Disease"],"enrollment":120,"completionDate":"2024-12-31"},{"nctId":"NCT05236387","phase":"","title":"Evaluating the Ability of 99mTc-Tilmanocept to Identify Clipped Nodes in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy and Sentinel Lymph Node Dissection","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2022-03-01","conditions":["Breast Cancer"],"enrollment":14,"completionDate":"2023-06-30"},{"nctId":"NCT04096716","phase":"PHASE1","title":"Mapping Draining Lymph Nodes in CNS Malignancies","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2019-12-03","conditions":["Central Nervous System Neoplasms","Central Nervous System Tumor"],"enrollment":14,"completionDate":"2022-04-30"},{"nctId":"NCT04663126","phase":"EARLY_PHASE1","title":"Feasibility of IV Tc-99m-tilmanocept for Imaging of M2-like TAMs in Metastatic Melanoma","status":"TERMINATED","sponsor":"John O. Prior","startDate":"2021-02-01","conditions":["Melanoma"],"enrollment":5,"completionDate":"2023-06-19"},{"nctId":"NCT04511026","phase":"PHASE2","title":"Concurrent Use Lymphoseek & Indocyanine Green in Sentinel Lymph Node Detection in Endometrial Cancer","status":"TERMINATED","sponsor":"Stanford University","startDate":"2021-01-20","conditions":["Endometrial Cancer"],"enrollment":6,"completionDate":"2021-06-10"},{"nctId":"NCT03938636","phase":"PHASE2","title":"Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value (TUV) on Tc 99m Tilmanocept Planar Imaging","status":"COMPLETED","sponsor":"Navidea Biopharmaceuticals","startDate":"2019-04-08","conditions":["Rheumatoid Arthritis"],"enrollment":116,"completionDate":"2021-06-30"},{"nctId":"NCT03405142","phase":"PHASE2","title":"Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer","status":"COMPLETED","sponsor":"Eben Rosenthal","startDate":"2019-08-01","conditions":["Head and Neck Squamous Cell Carcinoma","Squamous Cell Carcinoma of the Head and Neck (SCCHN)","Head and Neck Cancer"],"enrollment":3,"completionDate":"2021-04-27"},{"nctId":"NCT02865434","phase":"PHASE1,PHASE2","title":"Evaluating Safety of Escalating Doses of Tilmanocept by IV Injection and SPECT Imaging in Subjects With and Without RA","status":"COMPLETED","sponsor":"Navidea Biopharmaceuticals","startDate":"2017-01","conditions":["Arthritis, Rheumatoid"],"enrollment":39,"completionDate":"2018-06"},{"nctId":"NCT01902953","phase":"PHASE2","title":"Lymphoseek® as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC)","status":"COMPLETED","sponsor":"Maimonides Medical Center","startDate":"2013-03","conditions":["Colon Cancer","Rectal Cancer"],"enrollment":16,"completionDate":"2016-06"},{"nctId":"NCT04487912","phase":"PHASE4","title":"Dynamics and Tracer Distribution of Tilmanocept in Early Stage Breast Cancer","status":"WITHDRAWN","sponsor":"University Hospital, Ghent","startDate":"2020-11-24","conditions":["Breast Cancer","Sentinel Lymph Node"],"enrollment":0,"completionDate":"2021-05-01"},{"nctId":"NCT03029988","phase":"PHASE1","title":"An Evaluation of Tilmanocept by IV Injection Using SPECT/CT vs PET Imaging in Subjects With Liver Metastases.","status":"TERMINATED","sponsor":"Navidea Biopharmaceuticals","startDate":"2017-07-26","conditions":["Liver Metastases","Colorectal Carcinoma"],"enrollment":3,"completionDate":"2018-09-24"},{"nctId":"NCT02287675","phase":"PHASE4","title":"Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer","status":"COMPLETED","sponsor":"Kettering Health Network","startDate":"2015-01-19","conditions":["Breast Cancer"],"enrollment":40,"completionDate":"2017-08-31"},{"nctId":"NCT04261179","phase":"PHASE4","title":"Study Comparing Lymphoseek® vs. Albumin Nanocolloid in Head and Neck, Melanoma and Breast Cancer","status":"UNKNOWN","sponsor":"Anna Cruceta","startDate":"2020-03","conditions":["Head Cancer","Neck Cancer","Melanoma","Breast Cancer"],"enrollment":30,"completionDate":"2021-08"},{"nctId":"NCT02683421","phase":"PHASE1","title":"Evaluation of SC Injected Tc 99m Tilmanocept Localization in Active RA Subjects by SPECT and SPECT/CT Imaging","status":"COMPLETED","sponsor":"Navidea Biopharmaceuticals","startDate":"2016-07","conditions":["Rheumatoid Arthritis"],"enrollment":18,"completionDate":"2016-12"},{"nctId":"NCT02065232","phase":"","title":"Sentinel Lymph Node Mapping Post-Injection Site Pain","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2014-03","conditions":["Breast Cancer"],"enrollment":52,"completionDate":"2015-02"},{"nctId":"NCT02509585","phase":"PHASE2","title":"A Trial of Comparing the Pathology Status of Lymphoseek®-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection","status":"TERMINATED","sponsor":"Cardinal Health 414, LLC","startDate":"2016-01","conditions":["Uterine Cervical Neoplasms"],"enrollment":18,"completionDate":"2017-07"},{"nctId":"NCT02589366","phase":"PHASE1","title":"Lymphoseek as Lymphoid Tissue Targeting Agent in Patients With Cancer of the Endometrium","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2015-11","conditions":["Endometrial Cancer"],"enrollment":2,"completionDate":"2018-04"},{"nctId":"NCT03241446","phase":"PHASE1","title":"Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)","status":"WITHDRAWN","sponsor":"Navidea Biopharmaceuticals","startDate":"2017-09","conditions":["Arthritis, Rheumatoid"],"enrollment":0,"completionDate":"2018-03"},{"nctId":"NCT03199560","phase":"PHASE4","title":"Tilmanocept vs Sulfur Colloid in Sentinel Lymph Node Biopsy","status":"UNKNOWN","sponsor":"Memorial Health University Medical Center","startDate":"2017-06-22","conditions":["Sentinel Lymph Node Biopsy","Breast Cancer"],"enrollment":86,"completionDate":"2019-08-22"},{"nctId":"NCT02857608","phase":"PHASE2","title":"A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus","status":"WITHDRAWN","sponsor":"Cardinal Health 414, LLC","startDate":"2016-09","conditions":["Anal Cancer"],"enrollment":0,"completionDate":"2017-08"},{"nctId":"NCT02201420","phase":"PHASE2","title":"Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT","status":"COMPLETED","sponsor":"Navidea Biopharmaceuticals","startDate":"2014-09","conditions":["Kaposi's Sarcoma"],"enrollment":5,"completionDate":"2015-10"},{"nctId":"NCT00911326","phase":"PHASE3","title":"Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma","status":"TERMINATED","sponsor":"Navidea Biopharmaceuticals","startDate":"2009-05","conditions":["Head and Neck Squamous Cell Carcinoma (HNSCC)"],"enrollment":101,"completionDate":"2013-08"},{"nctId":"NCT00671918","phase":"PHASE3","title":"Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma","status":"COMPLETED","sponsor":"Navidea Biopharmaceuticals","startDate":"2008-04","conditions":["Breast Cancer","Melanoma"],"enrollment":186,"completionDate":"2009-07"},{"nctId":"NCT01106040","phase":"PHASE3","title":"Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes","status":"COMPLETED","sponsor":"Navidea Biopharmaceuticals","startDate":"2010-06","conditions":["Breast Cancer","Melanoma"],"enrollment":163,"completionDate":"2011-04"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"MMSL":"203086","UNII":"8IHI69PQTC","VANDF":"4038731","RXNORM":"1373391","UMLSCUI":"C3555537","chemblId":"CHEMBL2108726","ChEMBL_ID":"CHEMBL2108726","DRUGBANK_ID":"DB09266","SECONDARY_CAS_RN":"1262984-82-6","MESH_SUPPLEMENTAL_RECORD_UI":"C431884"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2013-","companyName":"Navidea Biopharms","relationship":"Original Developer"}],"publicationCount":3,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"V09IA09","allCodes":["V09IA09"]},"biosimilarFilings":[],"originalDeveloper":"Navidea Biopharms","recentPublications":[{"date":"2006","pmid":"29999773","title":"Technetium Tc 99m Tilmanocept.","journal":""},{"date":"2022 Oct","pmid":"35958955","title":"Technetium Tc 99m tilmanocept fails to detect sentinel lymph nodes in endometrial cancer.","journal":"Gynecologic oncology reports"},{"date":"2017 Apr 15","pmid":"28204544","title":"Application of a Novel CD206+ Macrophage-Specific Arterial Imaging Strategy in HIV-Infected Individuals.","journal":"The Journal of infectious diseases"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Navidea Biopharms","companyId":"navidea-biopharms","modality":"Recombinant protein","firstApprovalDate":"2013","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2013-03-13T00:00:00.000Z","mah":"NAVIDEA BIOPHARMS","brand_name_local":null,"application_number":""},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"2013-03-13T00:00:00.000Z","mah":"NAVIDEA BIOPHARMS","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"2013-03-13T00:00:00.000Z","mah":"NAVIDEA BIOPHARMS","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"2013-03-13T00:00:00.000Z","mah":"NAVIDEA BIOPHARMS","brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"2013-03-13T00:00:00.000Z","mah":"NAVIDEA BIOPHARMS","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"2013-03-13T00:00:00.000Z","mah":"NAVIDEA BIOPHARMS","brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"6409990","territory":"US","patent_type":null,"expiry_date":"2025-05-12T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9439985","territory":"US","patent_type":null,"expiry_date":"2029-01-30T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:33:36.556766+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}